Stocktoria
Centessa Pharmaceuticals plc CNTA
Centessa Pharmaceuticals plc (CNTA) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $15.0M at a -1316.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-04-20 | Wells Fargo | Equal-Weight (down) |
| 2026-04-02 | Guggenheim | Neutral (down) |
| 2026-04-01 | Leerink Partners | Market Perform (down) |
| 2026-03-31 | Wolfe Research | Peer Perform (down) |
| 2026-03-31 | Needham | Hold (down) |
| 2026-02-24 | Wolfe Research | Outperform (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1961 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.473 |
| Retained earnings / assets | -1.725 |
| EBIT / assets | -0.302 |
| Equity / liabilities | 3.28 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | 4/9 | -1.11 | — | — |
| NEUP | Neuphoria Therapeutics Inc. | 4/9 | -16.04 | — | — |
| IRD | Opus Genetics, Inc. | 3/9 | -11.42 | — | +29.1% |
| ABUS | Arbutus Biopharma Corp | 3/9 | — | — | — |
| QURE | uniQure N.V. | 4/9 | -1.71 | — | -40.6% |
| PYXS | Pyxis Oncology, Inc. | 2/9 | -16.86 | — | -14.2% |
| ZYBT | Zhengye Biotechnology Holding Ltd | 4/9 | 1.49 | — | -91.1% |
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
FAQ
Is CNTA financially healthy?
Centessa Pharmaceuticals plc's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CNTA pay a dividend?
No, Centessa Pharmaceuticals plc does not currently pay a dividend.
How profitable is CNTA?
In FY2025, Centessa Pharmaceuticals plc had a net margin of -1316.9% and a return on equity of -37.5%.
What is the analyst price target for CNTA?
The average Wall-Street price target for Centessa Pharmaceuticals plc is $40.25, from 4 analysts (consensus: hold).
Is CNTA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Centessa Pharmaceuticals plc: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.